Explore every episode of the podcast DoctoRx Unscripted

Highlights include:
• Early detection and the potential of screening studies like PROMISE and iStopMM
• Modifiable risk factors—how diet, exercise, and inflammation shape disease and outcomes
• Emerging therapies on the horizon
• Why “down with dex” and other old beliefs deserve retirement
• The personal “why” behind every advance in myeloma care

About the Experts

Dr. Paul Richardson

Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.

Dr. Richardson is a paid consultant for BMS.

Dr. Joseph Mikhael
Dr. Joseph Mikhael has revolutionized and broadened access to world-class myeloma care globally through his pioneering leadership at TGen and the International Myeloma Foundation and as principal investigator of numerous groundbreaking clinical trials, setting new benchmarks in innovation, impact, and equity. Celebrated as a dynamic champion for underserved communities, an award-winning educator, and a masterful communicator, Dr. Mikhael has authored over 150 influential scientific articles and was recently recognized among America’s Top 100 Doctors for his transformational contributions to the field.

Dr. Mikhael was not compensated for his participation.

Dr. Mecide Gharibo

Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.

Dr. Gharibo is an employee of BMS.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Highlights include:
• How MRD is reshaping drug development and accelerating innovation
• The evolution of next-generation and targeted therapies with the goal of achieving deeper and more durable remissions
• New thinking on “hit hard early” vs “save the best for last” treatment strategies
• The impact of race, biology, and access on outcomes—and what’s changing that trajectory

If you want to understand the science, urgency, and humanity driving today’s breakthroughs, this episode is your front-row seat to the bleeding edge of discovery.

About the Experts

Dr. Paul Richardson

Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.

Dr. Richardson is a paid consultant for BMS.

Dr. Joseph Mikhael
Dr. Joseph Mikhael has revolutionized and broadened access to world-class myeloma care globally through his pioneering leadership at TGen and the International Myeloma Foundation and as principal investigator of numerous groundbreaking clinical trials, setting new benchmarks in innovation, impact, and equity. Celebrated as a dynamic champion for underserved communities, an award-winning educator, and a masterful communicator, Dr. Mikhael has authored over 150 influential scientific articles and was recently recognized among America’s Top 100 Doctors for his transformational contributions to the field.

Dr. Mikhael was not compensated for his participation.

Dr. Mecide Gharibo

Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.

Dr. Gharibo is an employee of BMS.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Tania Small sits down with Dr. Heinz-Josef Lenz, one of the world’s greatest minds in gastrointestinal medical research, for a thought-provoking conversation on the future of colorectal cancer (CRC) care. 

Together, they unpack the rising incidence of early-onset CRC and the factors driving the surge of new cases in younger patients. This conversation dives into cutting-edge innovations that are reshaping detection and treatment: 

• ctDNA liquid biopsies and minimal residual disease testing - revolutionizing how relapse is detected.
• Next-generation diagnostics and precision screening, including AI-assisted colonoscopies - enabling earlier, more accurate identification.
• Methylation profiling, tumor microenvironment and epigenetic therapies - advancing personalized therapy and novel treatments.
• Immunotherapies and targeted agents - moving to the “front line” with the potential to transform treatment approaches into organ-preserving strategies.

But the conversation doesn’t stop at science. Together, they examine the influence of lifestyle, disparities in access, and patient-driven data on survival. 

If you're driving change in oncology, this episode offers practical insights on integrating molecular testing, rethinking prevention, and preparing for the innovations ahead. 

About Dr Heinz-Josef Lenz

Heinz-Josef Lenz, MD, is an award-winning trailblazer and mentor whose pioneering work in colorectal cancer gene regulation, drug resistance, early detection and surveillance has reshaped the field of oncology. He is the recipient of multiple prestigious honors, including the ASCO Young Investigator Award, Career Development Award and the USC Mentoring Award, celebrating his excellence in both research and mentorship. Dr Lenz also serves on national committees including SWOG, NCI Task Forces and advisory boards and has authored numerous peer-reviewed publications. 

Dr Lenz is a professor of medicine, Preventive Medicine and Cancer Biology J Terrence Lanni chair in Cancer Research. He is also deputy Cancer Center director at USC Norris and co-director of USC Brown Center for Cancer Drug Development. 

Dr. Heinz-Josef Lenz is a paid BMS consultant.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this special edition of DoctoRx Unscripted, Dr. Tania Small sits down with three of the most visionary leaders in oncology, Dr. Lillian Siu, Dr. Fabrice André and Dr. Howard “Skip” Burris for a provocative conversation on data that has the potential to redefine the future of cancer care.

They unpack cutting-edge findings—from next-generation diagnostics and novel modalities to AI-powered trials, precision medicine, prevention and what’s coming next in oncology innovation. 

But the conversation goes beyond the data and tackles the decisions, behaviors and systems needed to shape real-world outcomes.

They explore how lifestyle modifications may enhance treatment, efficacy and survival, and what it will take to improve global access to optimal cancer care and provide lasting impact through patient-driven science and purposeful action. 

This unforgettable episode spotlights the potential breakthroughs poised to detect cancer earlier and challenge conventional paradigms, with the goal of delivering better outcomes for patients worldwide.

If you're a clinician, researcher, or advocate at the forefront of oncology, this is your front-row seat to the future told by the pioneers shaping it.

Dr. André, Dr. Burris and Dr. Siu are paid consultants for BMS. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Dr. Tania Small, in a compelling 2-part episode featuring Dr. George Grossberg, a world-renowned geriatric psychiatrist who's been at the forefront of Alzheimer’s disease research and innovation for over 40 years. With over 400 papers to his name, Dr. Grossberg brings unparalleled insights into the disease. 

In part 2, they delve into groundbreaking science - from researching novel therapeutic targets and addressing Alzheimer’s psychosis to the power of patient-driven science in research and prevention. 

It is a forward-looking conversation that equips you with new cutting-edge insights for the future. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join Dr. Tania Small, in a compelling 2-part episode featuring Dr. George Grossberg, a world-renowned geriatric psychiatrist who's been at the forefront of Alzheimer’s disease research and innovation for over 40 years. With over 400 papers to his name, Dr. Grossberg brings unparalleled insights into the disease. 

In part 1, they uncover the subtle early signs of Alzheimer’s, the biomarker revolution, and tackle the challenges of health equity in Alzheimer’s care.  

It’s an insightful discussion that prepares you for future trends. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

What happens when someone in the grip of a psychotic break commits a crime? 
Do we brand them a criminal forever—or recognize a human being still worthy of evidence-based care, rehabilitation, and a true second chance? 

In this episode of DoctoRx Unscripted, host Dr. Tania Small sits down with renowned forensic psychiatrist Dr. Ilan Melnick to confront that dilemma head-on. 

Dr. Melnick directs a dignity-first program that blends comprehensive psychiatric treatment, cognitive-restoration therapy, trauma-informed support, and structured community re-entry. The outcomes are extraordinary: 0 percent recidivism and 90 percent sustained reintegration—results that upend long-held assumptions about severe mental illness, justice, and what true healing can look like. 

Together, Drs. Small and Melnick unpack how this model works, why it succeeds, and how clinicians can begin adapting its principles today. This conversation reveals what becomes possible when we treat the person behind the psychosis—with dignity, rigorous care, and a roadmap for real-world impact. 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In the premiere episode of DoctoRx Unscripted — Dr. Tania Small sits down with globally respected psychiatrist, Dr. John Kane, to unpack the science, challenge entrenched assumptions, and reimagine what schizophrenia care can be.

They take a provocative look at the future of psychiatry — unraveling the biology of schizophrenia, early psychosis and relapse, decoding the triad of symptoms, spotlighting emerging breakthroughs, rethinking the dopamine hypothesis, and showing how patient-driven science and partnerships are reshaping what’s possible in treating serious mental illness.

It’s a forward-looking conversation that equips you with fresh insights — and a new lens on what’s possible in psychiatry.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.